# Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms

> **NCT07679334** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Bone Marrow Aspiration

## Key facts

- **NCT ID:** NCT07679334
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679334, "Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*